Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Purchases $196,534.80 in Stock

Share on StockTwits

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Anthony G. Quinn acquired 31,905 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were bought at an average price of $6.16 per share, for a total transaction of $196,534.80. Following the acquisition, the chief executive officer now owns 333,955 shares in the company, valued at approximately $2,057,162.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Aeglea Bio Therapeutics stock opened at $6.18 on Monday. Aeglea Bio Therapeutics Inc has a twelve month low of $5.99 and a twelve month high of $11.37. The stock has a market cap of $178.28 million, a PE ratio of -2.90 and a beta of 0.95.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Analysts anticipate that Aeglea Bio Therapeutics Inc will post -2.14 earnings per share for the current year.

Several research firms have recently issued reports on AGLE. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Aeglea Bio Therapeutics in a report on Monday, June 3rd. JPMorgan Chase & Co. assumed coverage on shares of Aeglea Bio Therapeutics in a research report on Thursday, March 21st. They set an “overweight” rating and a $14.00 target price on the stock. Finally, ValuEngine lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 9th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Aeglea Bio Therapeutics presently has an average rating of “Hold” and a consensus price target of $14.33.

Several institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA acquired a new position in Aeglea Bio Therapeutics in the first quarter valued at about $32,000. Canada Pension Plan Investment Board acquired a new position in Aeglea Bio Therapeutics in the fourth quarter valued at about $37,000. Meeder Asset Management Inc. boosted its position in Aeglea Bio Therapeutics by 38.4% in the first quarter. Meeder Asset Management Inc. now owns 7,083 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,967 shares in the last quarter. Bank of America Corp DE boosted its position in Aeglea Bio Therapeutics by 299.9% in the fourth quarter. Bank of America Corp DE now owns 17,145 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 12,858 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in Aeglea Bio Therapeutics in the fourth quarter valued at about $156,000. Institutional investors and hedge funds own 68.48% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Purchases $196,534.80 in Stock” was posted by Macon Daily and is the property of of Macon Daily. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://macondaily.com/2019/06/17/aeglea-bio-therapeutics-inc-nasdaqagle-ceo-purchases-196534-80-in-stock.html.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

See Also: P/E Growth (PEG)

Insider Buying and Selling by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.